doi: 10.1021/acs.biomac.5b00168 [DOI] [PubMed] [Google Scholar] 89
[3] In REDEFINE 2 , a parallel 68-week Phase 3a trial in 1,206 adults who had overweight or obesity and type 2 diabetes, once-weekly CagriSema produced an estimated mean weight change of 13.7% versus 3.4% with placebo, alongside marked improvements in glycemic control
The most common experiences include slight nausea (particularly with first doses), minor fatigue or drowsiness, temporary dizziness, injection site reactions like mild redness or itching, and sleep disturbances (usually with evening dosing)
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name
Social Media is intended for U.S